[HTML][HTML] Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard, J Freyssenge… - European Journal of …, 2024 - academic.oup.com
Abstract Since June 2021 in France, patients with haemophilia A with anti-factor VIII
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
[PDF][PDF] Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard, J Freyssenge… - European Journal of …, 2024 - oxfordjournals.org
Abstract Since June 2021 in France, patients with haemophilia A with anti-factor VIII
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard, J Freyssenge… - European Journal of …, 2024 - academic.oup.com
Abstract Since June 2021 in France, patients with haemophilia A with anti-factor VIII
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France.
M Cabon, V Chamouard… - European Journal of …, 2024 - search.ebscohost.com
Abstract Since June 2021 in France, patients with haemophilia A with anti-factor VIII
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France.
M Cabon, V Chamouard, J Freyssenge… - European Journal of …, 2024 - europepmc.org
Since June 2021 in France, patients with haemophilia A with anti-factor VIII inhibitors and
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …
Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard… - European Journal of …, 2024 - univ-lyon1.hal.science
Since June 2021 in France, patients with haemophilia A with anti-factor VIII inhibitors and
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …
[HTML][HTML] Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard, J Freyssenge… - … European Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Abstract Since June 2021 in France, patients with haemophilia A with anti-factor VIII
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
inhibitors and patients with severe haemophilia A without anti-factor VIII inhibitors have the …
Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France
M Cabon, V Chamouard… - European journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Since June 2021 in France, patients with haemophilia A with anti-factor VIII inhibitors and
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …
patients with severe haemophilia A without anti-factor VIII inhibitors have the choice …